US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% AMZN $251.40 ▲+0.00% META $741.90 ▲+0.00% AMD $631.75 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00%
FinancialContent

Articles published by PharmAla Biotech

News headline image
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA JUNS MDXXF
News headline image
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
Cortexa Advances Commercialisation of MDMA Supply in Australia
From PharmAla Biotech
Via GlobeNewswire
Tickers ASX:VIT CSE:MDMA MDXXF
News headline image
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Contracts with Partner to Act as US Distributor
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Launches MDMA Clinical Trial Tool for Researchers
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA MDXXF
News headline image
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA
News headline image
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA PMBHF
News headline image
PharmAla Begins Trading on OTCQB
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA PMBHF
News headline image
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA PMBHF
News headline image
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA PMBHF
News headline image
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
From PharmAla Biotech
Via GlobeNewswire
Tickers ASX:VIT CSE:MDMA
News headline image
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA
News headline image
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
From PharmAla Biotech
Via GlobeNewswire
Tickers CSE:MDMA CSE:MSET MSSTF